Pyridam Farma (PYFA.JK)

Pyridam Farma stock price today, ATLAS forecast and fair value

Healthcare · Drug Manufacturers - Specialty & Generic · Indonesia Stock Exchange · Indonesia

IDR 157.00▼ -6.55%

Prices as of Oct 27, 2026 · IDR

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

45%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Pyridam Farma in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Pyridam Farma

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Pyridam Farma a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between IDR 132.19 and IDR 177.49; in 9 out of 10, between IDR 101.79 and IDR 230.49. Estimated annual volatility is 83%.

Price, last 12 months (weekly close)

Key numbers

Market cap: IDR 2.4T
Market cap (USD): $135M
52-week high: IDR 625.00
52-week low: IDR 157.00
Revenue (12 months): IDR 3.0T
Gross margin: 21.9%
Operating margin: -0.2%
Net margin: -11.5%
Beta: 0.82

What this means

ATLAS does not publish a fair value for PYFA.JK right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks PYFA.JK has traded between IDR 157.00 and IDR 625.00. Today it is 74.9% below that high and 0% above its low.

Its beta is 0.82: it tends to move less than the market.

About the company

PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments.

Want to see everything about Pyridam Farma?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Pyridam Farma do?

What is the chance PYFA.JK goes up next month?

45%: close to a coin flip. In half of the simulated outcomes, PYFA.JK ends the month between IDR 132.19 and IDR 177.49.

How big is Pyridam Farma and what is its P/E ratio?

Pyridam Farma's market capitalization is IDR 2.4T. We do not show a P/E because it has no positive earnings to base one on.

How volatile is PYFA.JK?

ATLAS estimates annual volatility at 83%. In a typical month, half of the outcomes end between IDR 132.19 and IDR 177.49.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer